Privia Health Group (NASDAQ:PRVA) CFO David Mountcastle Sells 600 Shares of Stock

Posted by Brian Himes on Jul 10th, 2026

Privia Health Group, Inc. (NASDAQ:PRVA – Get Free Report) CFO David Mountcastle sold 600 shares of the business’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $27.57, for a total value of $16,542.00. Following the completion of the transaction, the chief financial officer directly owned 186,128 shares in the company, valued at $5,131,548.96. This represents a 0.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Mountcastle also recently made the following trade(s):

On Thursday, July 2nd, David Mountcastle sold 24,734 shares of Privia Health Group stock. The stock was sold at an average price of $27.50, for a total transaction of $680,185.00.
On Friday, June 26th, David Mountcastle sold 17,196 shares of Privia Health Group stock. The shares were sold at an average price of $25.18, for a total transaction of $432,995.28.
On Monday, May 11th, David Mountcastle sold 3,385 shares of Privia Health Group stock. The stock was sold at an average price of $22.60, for a total value of $76,501.00.
On Monday, May 4th, David Mountcastle sold 1,206 shares of Privia Health Group stock. The shares were sold at an average price of $25.00, for a total transaction of $30,150.00.
On Friday, May 1st, David Mountcastle sold 7,179 shares of Privia Health Group stock. The shares were sold at an average price of $25.03, for a total transaction of $179,690.37.

Privia Health Group Price Performance

Shares of NASDAQ PRVA opened at $27.77 on Friday. The company has a 50-day moving average price of $23.71 and a 200-day moving average price of $23.11. The stock has a market capitalization of $3.50 billion, a P/E ratio of 173.57, a P/E/G ratio of 2.15 and a beta of 0.83. Privia Health Group, Inc. has a 1 year low of $18.77 and a 1 year high of $27.81.

Institutional Investors Weigh In On Privia Health Group

Several large investors have recently added to or reduced their stakes in PRVA. ArrowMark Colorado Holdings LLC purchased a new stake in Privia Health Group during the 3rd quarter worth about $8,750,000. Renaissance Group LLC purchased a new position in Privia Health Group during the 4th quarter valued at about $7,776,000. Principal Financial Group Inc. grew its holdings in Privia Health Group by 1.6% during the 4th quarter. Principal Financial Group Inc. now owns 2,787,802 shares of the company’s stock valued at $66,099,000 after buying an additional 43,589 shares in the last quarter. Algert Global LLC increased its position in shares of Privia Health Group by 277.4% during the third quarter. Algert Global LLC now owns 484,304 shares of the company’s stock valued at $12,059,000 after buying an additional 355,966 shares during the period. Finally, Louisiana State Employees Retirement System bought a new stake in shares of Privia Health Group during the first quarter valued at about $1,055,000. Hedge funds and other institutional investors own 94.48% of the company’s stock.

Analyst Ratings Changes

PRVA has been the subject of several analyst reports. Weiss Ratings raised Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, July 2nd. Barclays cut their target price on Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 26th. Canaccord Genuity Group reduced their target price on shares of Privia Health Group from $35.00 to $34.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Zacks Research lowered Privia Health Group from a “hold” rating to a “strong sell” rating in a report on Tuesday. Finally, Evercore set a $26.00 price target on Privia Health Group in a report on Wednesday, April 8th. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $31.15.

Get Our Latest Report on PRVA

About Privia Health Group

(Get Free Report)

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.